Pfizer: Early Trial Data Suggests Updated COVID-19 Booster Protects Against Omicron
Pfizer and its partner BioNTech reported on Thursday that the shots elicit more antibodies that fight the omicron subvariants BA.4 and BA.5 than the original coronavirus shot one week after the shots were administered. The shot was well tolerated with positive safety data similar to that of the original vaccine, according to Pfizer. Awesome!
Photo Credit: Markus Spiske